{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:40:51Z","timestamp":1759365651215,"version":"build-2065373602"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"DOI":"10.7759\/cureus.93632","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:04:57Z","timestamp":1759309497000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evaluation of Early Initiation of Dapagliflozin and Sitagliptin Combination Therapy in the Management of Type 2 Diabetes Mellitus (REALIZE Study)"],"prefix":"10.7759","author":[{"given":"Sambit","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SK","family":"Wangnoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasun","family":"Deb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Pednekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan N","family":"Kesarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88460-z","article-title":"Assessing type-2 diabetes risk based on the Indian diabetes risk score among adults aged 45 and above in India","volume":"15","author":"Maniyara K","year":"2025","unstructured":"Maniyara K, Kodali PB. Assessing type-2 diabetes risk based on the Indian diabetes risk score among adults aged 45 and above in India. Sci Rep. 2025, 15:4495. 10.1038\/s41598-025-88460-z","journal-title":"Sci Rep"},{"key":"ref2","article-title":"Sitagliptin as an add-on therapy to other glucose-lowering agents in patients with type 2 diabetes mellitus: a narrative review","volume":"73","author":"Kalra S","year":"2025","unstructured":"Kalra S, Singh A, Das S, et al.. Sitagliptin as an add-on therapy to other glucose-lowering agents in patients with type 2 diabetes mellitus: a narrative review. J Assoc Physicians India. 2025, 73:13-18.","journal-title":"J Assoc Physicians India"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2023.100155","article-title":"Association between abdominal obesity and diabetes in India: findings from a nationally representative study","volume":"12","author":"Gupta RD","year":"2023","unstructured":"Gupta RD, Kothadia RJ, Parray AA. Association between abdominal obesity and diabetes in India: findings from a nationally representative study. Diabet Epidemiol Manag. 2023, 12:100155. 10.1016\/j.deman.2023.100155","journal-title":"Diabet Epidemiol Manag"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20191035","article-title":"Consensus statement for the management of dyslipidemia and hypertension in the Indian population with diabetes","volume":"6","author":"Jayagopal PB","year":"2019","unstructured":"Jayagopal PB, Rao MS, Vijaykumar R, et al.. Consensus statement for the management of dyslipidemia and hypertension in the Indian population with diabetes. Int J Adv Med. 2019, 6:562. 10.18203\/2349-3933.ijam20191035","journal-title":"Int J Adv Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-2786. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes. Diabetes Care. 2024, 47:S158-S178. 10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107813","article-title":"Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management","volume":"35","author":"Kanumilli N","year":"2021","unstructured":"Kanumilli N, Brunton S, Cos X, Deed G, Kushner P, Lin P, Nolte J. Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management. J Diabetes Complications. 2021, 35:107813. 10.1016\/j.jdiacomp.2020.107813","journal-title":"J Diabetes Complications"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003769","article-title":"Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population","volume":"12","author":"Sivadas A","year":"2024","unstructured":"Sivadas A, Sahana S, Jolly B, et al.. Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population. BMJ Open Diabetes Res Care. 2024, 12:e003769. 10.1136\/bmjdrc-2023-003769","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050387","article-title":"Insights into the roles of GLP-1, DPP-4, and SGLT2 at the crossroads of cardiovascular, renal, and metabolic pathophysiology","volume":"14","author":"Gaggini M","year":"2025","unstructured":"Gaggini M, Sabatino L, Suman AF, Chatzianagnostou K, Vassalle C. Insights into the roles of GLP-1, DPP-4, and SGLT2 at the crossroads of cardiovascular, renal, and metabolic pathophysiology. Cells. 2025, 14:387. 10.3390\/cells14050387","journal-title":"Cells"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-35","article-title":"Effects of sitagliptin beyond glycemic control: focus on quality of life","volume":"12","author":"Sakamoto Y","year":"2013","unstructured":"Sakamoto Y, Oyama J, Ikeda H, et al.. Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol. 2013, 12:35. 10.1186\/1475-2840-12-35","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan S","year":"2020","unstructured":"Gan S, Dawed AY, Donnelly LA, Nair AT, Palmer CN, Mohan V, Pearson ER. Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2020, 43:1948-1957. 10.2337\/dc19-2419","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.01.011","article-title":"Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis","volume":"44","author":"Cho YK","year":"2018","unstructured":"Cho YK, Kang YM, Lee SE, et al.. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2018, 44:393-401. 10.1016\/j.diabet.2018.01.011","journal-title":"Diabetes Metab"},{"key":"ref13","article-title":"Clinical benefits of fixed dose combinations translated to improved patient compliance","volume":"67","author":"Arya DS","year":"2019","unstructured":"Arya DS, Chowdhury S, Chawla R, et al.. Clinical benefits of fixed dose combinations translated to improved patient compliance. J Assoc Physicians India. 2019, 67:58-64.","journal-title":"J Assoc Physicians India"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20250018","article-title":"Synergizing sodium-dependent glucose transporter inhibitors with dipeptidyl-peptidase 4 inhibitor and metformin: a novel approach to diabetes management in India","volume":"14","author":"Ayyar V","year":"2025","unstructured":"Ayyar V, Ommen T, Shukla RP, et al.. Synergizing sodium-dependent glucose transporter inhibitors with dipeptidyl-peptidase 4 inhibitor and metformin: a novel approach to diabetes management in India. Int J Basic Clin Pharmacol. 2025, 14:160-164. 10.18203\/2319-2003.ijbcp20250018","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60815","article-title":"Retrospective observational study on assessing sitagliptin and dapagliflozin as a fixed-dose combination in the Indian population with type 2 diabetes mellitus: the SIDAXA study","volume":"16","author":"Chawla M","year":"2024","unstructured":"Chawla M, Panneerselvam D, Gundgurthy A, et al.. Retrospective observational study on assessing sitagliptin and dapagliflozin as a fixed-dose combination in the Indian population with type 2 diabetes mellitus: the SIDAXA study. Cureus. 2024, 16:e60815. 10.7759\/cureus.60815","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-014-0476-5","article-title":"Diabetes and associated complications in the South Asian population","volume":"16","author":"Shah A","year":"2014","unstructured":"Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. Curr Cardiol Rep. 2014, 16:476. 10.1007\/s11886-014-0476-5","journal-title":"Curr Cardiol Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2715-x","article-title":"The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study","volume":"56","author":"Scott RA","year":"2013","unstructured":"Scott RA, Langenberg C, Sharp SJ, et al.. The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study. Diabetologia. 2013, 56:60-69. 10.1007\/s00125-012-2715-x","journal-title":"Diabetologia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2013.10.88","article-title":"Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients","volume":"10","author":"Chen SC","year":"2013","unstructured":"Chen SC, Tseng CH. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud. 2013, 10:88-100. 10.1900\/RDS.2013.10.88","journal-title":"Rev Diabet Stud"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1156081","article-title":"Medication adherence with fixed-dose versus free-equivalent combination therapies: systematic review and meta-analysis","volume":"14","author":"Wei Q","year":"2023","unstructured":"Wei Q, Zhou J, Li H, Wang L, Wu Y, Ma A, Guan X. Medication adherence with fixed-dose versus free-equivalent combination therapies: systematic review and meta-analysis. Front Pharmacol. 2023, 14:1156081. 10.3389\/fphar.2023.1156081","journal-title":"Front Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12001","article-title":"Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation","volume":"28","author":"Derosa G","year":"2014","unstructured":"Derosa G, Ragonesi PD, Fogari E, et al.. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol. 2014, 28:221-229. 10.1111\/fcp.12001","journal-title":"Fundam Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-8-23","article-title":"Postprandial hyperglycemia as an etiological factor in vascular failure","volume":"8","author":"Node K","year":"2009","unstructured":"Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009, 8:23. 10.1186\/1475-2840-8-23","journal-title":"Cardiovasc Diabetol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.14740\/jem1055","article-title":"The BRIDGE-DS study: improved glycemic control and renal function in type 2 diabetes mellitus patients using the fixed-dose combination of dapagliflozin and sitagliptin","author":"Maiti A","year":"2025","unstructured":"Maiti A, Pandey AK, Kale S, et al.. The BRIDGE-DS study: improved glycemic control and renal function in type 2 diabetes mellitus patients using the fixed-dose combination of dapagliflozin and sitagliptin. J Endocrinol Metab. 2025, 10.14740\/jem1055","journal-title":"J Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_19_24","article-title":"Expert opinion on fixed dose combination of dapagliflozin plus sitagliptin for unmet cardiovascular benefits in type 2 diabetes mellitus","volume":"15","author":"Ray S","year":"2024","unstructured":"Ray S, Ezhilan J, Karnik R, et al.. Expert opinion on fixed dose combination of dapagliflozin plus sitagliptin for unmet cardiovascular benefits in type 2 diabetes mellitus. JODB. 2024, 15:131-141. 10.4103\/jod.jod_19_24","journal-title":"JODB"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.04.009","article-title":"The association between triglycerides and incident cardiovascular disease: What is \"optimal\"?","volume":"14","author":"Aberra T","year":"2020","unstructured":"Aberra T, Peterson ED, Pagidipati NJ, et al.. The association between triglycerides and incident cardiovascular disease: What is \"optimal\"?. J Clin Lipidol. 2020, 14:438.e3-447.e3. 10.1016\/j.jacl.2020.04.009","journal-title":"J Clin Lipidol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.99.EP639","article-title":"Real-world effectiveness of dapagliflozin and sitagliptin fixed-dose combination in indian patients with type 2 diabetes: a retrospective analysis of electronic medical records stratified by BMI","author":"Kovil R","year":"2024","unstructured":"Kovil R, Deshmane R, Bharathi BP, et al.. Real-world effectiveness of dapagliflozin and sitagliptin fixed-dose combination in indian patients with type 2 diabetes: a retrospective analysis of electronic medical records stratified by BMI. EJEA. 2024, 10.1530\/endoabs.99.EP639","journal-title":"EJEA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46767","article-title":"The real DAPSI: a real-world retrospective study on assessing the efficacy and safety of a fixed-dose combination of dapagliflozin and sitagliptin in the Indian population","volume":"15","author":"Bhattacharjee R","year":"2023","unstructured":"Bhattacharjee R, Rai M, Joshi P, Prasad A, Birla A. The real DAPSI: a real-world retrospective study on assessing the efficacy and safety of a fixed-dose combination of dapagliflozin and sitagliptin in the Indian population. Cureus. 2023, 15:e46767. 10.7759\/cureus.46767","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.07.007","article-title":"Racial comparison of the pharmacokinetics and safety of fixed-dose combination of dapagliflozin\/sitagliptin in Western and Korean healthy adults","volume":"46","author":"Lukka PB","year":"2024","unstructured":"Lukka PB, Tang W, Hammarstedt A, Conrad T, Heijer M, Karlsson C, Boulton DW. Racial comparison of the pharmacokinetics and safety of fixed-dose combination of dapagliflozin\/sitagliptin in Western and Korean healthy adults. Clin Ther. 2024, 46:717-725. 10.1016\/j.clinthera.2024.07.007","journal-title":"Clin Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01219-x","article-title":"Expert opinion: optimum clinical approach to combination-use of SGLT2i\u2009+\u2009DPP4i in the Indian diabetes setting","volume":"13","author":"Chadha M","year":"2022","unstructured":"Chadha M, Das AK, Deb P, et al.. Expert opinion: optimum clinical approach to combination-use of SGLT2i\u2009+\u2009DPP4i in the Indian diabetes setting. Diabetes Ther. 2022, 13:1097-1114. 10.1007\/s13300-022-01219-x","journal-title":"Diabetes Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_162_17","article-title":"Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus","volume":"22","author":"Kalra S","year":"2018","unstructured":"Kalra S, Kesavadev J, Chadha M, Kumar GV. Sodium-glucose cotransporter-2 inhibitors in combination with other glucose-lowering agents for the treatment of type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018, 22:827-836. 10.4103\/ijem.IJEM_162_17","journal-title":"Indian J Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404536-real-world-evaluation-of-early-initiation-of-dapagliflozin-and-sitagliptin-combination-therapy-in-the-management-of-type-2-diabetes-mellitus-realize-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:04:59Z","timestamp":1759309499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404536-real-world-evaluation-of-early-initiation-of-dapagliflozin-and-sitagliptin-combination-therapy-in-the-management-of-type-2-diabetes-mellitus-realize-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.93632","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}